Camurus Provides Regulatory Update on the US NDA for CAM2029 (Oclaiz™) in Acromegaly

Дата публикации: 10-06-2026 02:06:27

Lund, Sweden — 10 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (Oclaiz™)...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA	0	10.06	17-07-2026
2	Ascelia Pharma Provides Update on the Orviglance NDA	0	11.3	03-07-2026
3	Sobi Receives Complete Response Letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)	0	9.15	26-06-2026
4	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	0	9.64	22-06-2026
5	Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)	0	13.98	30-06-2026
6	Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026	0	15.84	28-07-2026
7	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
8	Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA	0	13.35	22-06-2026
9	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility	0	13.33	07-08-2026
10	GSK Provides an Update on CALM-1 and CALM-2 Phase III Trials for Camlipixant in Refractory Chronic Cough (RCC)	0	7.48	17-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.28. Источник: www.drugs.com.